Back to results
US 2026/0200923 A1Published application
Heterocyclic compounds targeting the nudt5 protein
AssigneeOxford University Innovation Limited
InventorsKilian HUBER, Anne-Sophie MARQUES, Stefan KUBICEK, George LIN
Life of this patent
Estimating the term…
Abstract
The invention concerns compounds which are useful in targeting and degrading the NUDT5 protein. The invention also concerns the compounds of the invention for use in methods of treatment, particularly for use in treatment of cancer, inflammatory disorders and folate-related disorders, as well as to reduce the side-effects and/or toxicity of a second drug. The invention further concerns screening methods.
Claims24
A compound of formula (I):
- or a pharmaceutically acceptable salt thereof,
- wherein X is a moiety capable of binding to NUDT5;
- L is a linker comprising at least one heterocyclic moiety, said heterocyclic moiety being a bivalent, saturated, nitrogen-containing heterocyclic moiety;
- and
- Y is a moiety capable of binding to E3 ligase.
2 more elements
A compound of formula (IA):
- or a pharmaceutically acceptable salt thereof,
- wherein X is a moiety capable of binding to NUDT5;
- LA is a linker of formula:
- wherein
- Z is O or S;
- p, q, r and s are each integers independently selected from 1, 2, 3 or 4, each q being independently selected from 1, 2, 3 or 4 where s>1;
- and
- Y is a moiety capable of binding to E3 ligase.
5 more elements
A compound of formula (IB):
- or a pharmaceutically acceptable salt thereof,
- wherein X is a moiety capable of binding to NUDT5;
- LB is a linker;
- and
- YB is a moiety capable of recruiting cellular destruction machinery, except that YB is not a moiety capable of binding to VHL or CRBN.
2 more elements
24-25. (canceled)
Dependencies are inferred from the claim text.